Jeong Yoon-sook
Sungkyunkwan University · Medicine
About the Lab
Professor Jeong Yoon-sook's research lab specializes in gastrointestinal and inflammatory diseases, with a strong focus on inflammatory bowel disease (IBD), Helicobacter pylori infection, and rare gastrointestinal conditions such as Behçet’s disease. The lab investigates novel therapeutic strategies, including vonoprazan-based eradication therapy for H. pylori and biosimilar infliximab (CT-P13) for IBD, emphasizing real-world efficacy and long-term outcomes. It also explores cancer risk in IBD patients and endoscopic management of small colorectal polyps, combining clinical research with translational insights for improved patient care.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15BACKGROUND: In order to increase eradication rates, vonoprazan, a novel potassium-competitive acid blocker, has been used in Helicobacter pylori eradication therapy. AIM: To summarise the results of the efficacy of vonoprazan-based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection. METHODS: We conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "vonoprazan," "takec
BACKGROUND AND AIM: A biosimilar of infliximab, CT-P13 (Remsima®) has the potential to reduce treatment costs and enhance access to biological therapy for inflammatory bowel disease (IBD) patients. However, long-term clinical data on its use for IBD treatment are currently sparse. We aimed to investigate the long-term efficacy and safety of CT-P13 therapy in a large, real-life IBD cohort. METHODS: A total of 368 IBD patients (227 with Crohn's disease [CD] and 141 with ulcerative colitis [UC]) tr
BACKGROUND AND AIMS: The association between inflammatory bowel disease [IBD] and cancer remains poorly defined in Asian populations. Therefore, we conducted a nationwide population-based study to determine the cancer risk in Korean patients with IBD. METHODS: Using the National Health Insurance claims data, we collected data on patients diagnosed with IBD (5595 Crohn's disease [CD] and 10 049 ulcerative colitis [UC]) from 2011 to 2014. Standardized incidence ratios [SIRs] of overall and site-sp
BACKGROUND: To date there have been few studies regarding the efficacy of surgical treatment and related prognostic factors following intestinal resection in patients with intestinal Behcet's disease (BD). Here we investigated the long-term clinical outcomes and related prognostic factors after surgical treatment for intestinal BD. METHODS: We reviewed the medical records of 72 patients with intestinal BD who underwent surgery between March 1986 and May 2010. Prognostic factors were identified b
In this small study approximately 90 % of all diminutive polyps and 100% of 1-3-mm adenomatous polyps were completely resected using CBP and chromoendoscopy. CBP appears to be adequate for the resection of the majority of diminutive polyps, especially small sized adenomas (≤ 3 mm) if no residual tissue is visible by chromoendoscopy.
This study has shown that 5-ASA/sulfasalazine therapy has a positive effect in maintaining remission in patients with intestinal BD. However, a younger age (<35 y), higher C-reactive protein level (≥1.5 mg/dL), and a higher disease activity index for intestinal Behcet disease score (≥60) were associated with a poor response to 5-ASA/sulfasalazine therapy, making careful observation and intensive treatment necessary in these risk groups.
BACKGROUND: The incidence of rectal neuroendocrine tumors (NET) has been increasing since the implementation of the screening colonoscopy. However, very little is known about risk factors associated with rectal NETs. We examined the prevalence of and the risk factors for rectal NETs in a Korean population. METHODS: A cross-sectional study was performed on 62,171 Koreans who underwent screening colonoscopy. The clinical characteristics and serum biochemical parameters of subjects with rectal NET
Physical inactivity and metabolic abnormalities are associated with reduced NK cell activity. Immune systems may become altered depending on physical activity and metabolic status.
There were no significant differences in the long-term clinical outcomes and postoperative prognoses between CD and intestinal BD, although CD patients required corticosteroid or immunosuppressant therapy more often than intestinal BD patients.
Abstract Background and Aim Although it is known that metformin can reduce risk of colorectal cancer, it is unclear whether it protects against colorectal adenoma. Methods This study conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords “colorectal,” “colon,” “rectal,” “rectum,” “adenoma,” “polyp,” “neoplasia,” “neoplasm,” “metformin,” and “diabetes.” Studies were included if they evaluated the association between metformin use and color
Research Areas
Dive deeper into Jeong Yoon-sook's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.